On-Demand Digital Health Monthly:
Scientific Webinar Series
Monitoring Activity and Gait in Children using DHTs
Digital Health Monthly: Scientific Webinar Series
Sensor-based DHTs are shedding an illuminating light on how people function in their real-world environments. Drug developers, researchers, patients, and regulators are realizing the multifaceted value sensor-based DHTs can bring to clinical research.
As their adoption continues to grow, we at ActiGraph are excited to launch ‘Digital Health Monthly’, a new monthly series of science-focused webinars to share the latest high-impact developments in clinical research from innovators in the digital health field. Each monthly webinar will feature brief data-driven presentations from clinical researchers, data scientists, and biostatisticians on a focused topic with dedicated time for audience Q&A. We believe that together, we can move the digital health technology field forward faster, and we are excited for this opportunity to facilitate important discussions on the latest research with members of the digital health community.
Monitoring Activity and Gait in Children using DHTs
Measures of physical activity and gait can provide key insights in understanding an individual’s mobility, their overall health and quality of life. Digital health technologies (DHTs) are now being widely used to monitor physical activity and gait in adults, however, limited studies have validated these in pediatric populations. Further, while DHTs allow for passive and continuous monitoring of physical activity and mobility to inform patient functioning in the real world, the feasibility for use and the development of standardized measures and their validations are unmet needs for acceptance and use in pediatric clinical research.
In this 30-minute, third installment of the Digital Health Monthly scientific webinar series, we review new data from the Monitoring Activity and Gait in Children (MAGIC) study that evaluates DHT-measured gait and physical activity in pediatric participants (3-17 years). The specifics on the use of wearable DHTs in this population and considerations for study design and data analyses are discussed.
